110 related articles for article (PubMed ID: 38555741)
1. Identification of a cisplatin resistant-based prognostic immune related gene signature in MIBC.
Wu Y; Xu Z; Fu G; Chen X; Tian J; Cai H; Jiang P; Jin B
Transl Oncol; 2024 Jun; 44():101942. PubMed ID: 38555741
[TBL] [Abstract][Full Text] [Related]
2. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
3. A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer.
Zheng X; Zhou X; Xu H; Jin D; Yang L; Shen B; Qiu S; Ai J; Wei Q
Front Genet; 2021; 12():764184. PubMed ID: 34899849
[TBL] [Abstract][Full Text] [Related]
4. Identification and Immunocorrelation of Prognosis-Related Genes Associated With Development of Muscle-Invasive Bladder Cancer.
Li J; Lou Y; Li S; Sheng F; Liu S; Du E; Zhang Z
Front Mol Biosci; 2020; 7():598599. PubMed ID: 33604353
[TBL] [Abstract][Full Text] [Related]
5. LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients.
Zheng X; Liao X; Nie L; Lin T; Xu H; Yang L; Shen B; Qiu S; Ai J; Wei Q
Front Cell Dev Biol; 2021; 9():748280. PubMed ID: 35004669
[No Abstract] [Full Text] [Related]
6. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
7. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
8. Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Yu Y; Zeng H; Jin K; You R; Liu Z; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Cancer Immunol Immunother; 2022 Sep; 71(9):2117-2126. PubMed ID: 35041031
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
10. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer.
Zheng Z; Mao S; Zhang W; Liu J; Li C; Wang R; Yao X
Front Oncol; 2020; 10():542492. PubMed ID: 33392066
[TBL] [Abstract][Full Text] [Related]
12. Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer.
Shen C; Xu T; Sun Y; Wang L; Liang Z; Niu H; Jiao W; Wang Y
Dis Markers; 2020; 2020():8866730. PubMed ID: 33456631
[TBL] [Abstract][Full Text] [Related]
13. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
16. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Xie H; Fu Q; Dai B; Ye D; Xu J
Clin Cancer Res; 2018 Jul; 24(13):3069-3078. PubMed ID: 29514839
[No Abstract] [Full Text] [Related]
17. Cuproptosis-Related lncRNAs Modulate the Prognosis of MIBC by Regulating the Expression Pattern of Immunosuppressive Molecules Within the Tumor Microenvironment.
Duan H; Shen Y; Wang C; Xia W; Zhang S; Yu S; Xu D; Cao Q; Liu H; Shen H
Int J Gen Med; 2024; 17():161-174. PubMed ID: 38268861
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Nuclear Mitochondrial-Related Multi-Genes Signature to Predict the Prognosis of Bladder Cancer.
Jiang X; Xia Y; Meng H; Liu Y; Cui J; Huang H; Yin G; Shi B
Front Oncol; 2021; 11():746029. PubMed ID: 34692528
[TBL] [Abstract][Full Text] [Related]
19. Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
Shao F; Jin K; Li B; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Chang Y; Zhang W
Urol Oncol; 2023 Oct; 41(10):433.e9-433.e18. PubMed ID: 37625906
[TBL] [Abstract][Full Text] [Related]
20. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
